1. Home
  2. GALT

as 05-09-2025 3:36pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Founded: 2000 Country:
United States
United States
Employees: N/A City: NORCROSS
Market Cap: 86.0M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 177.8K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.76 EPS Growth: N/A
52 Week Low/High: $0.73 - $3.41 Next Earning Date: 05-19-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

GALT Daily Stock ML Predictions

Share on Social Networks: